

Table S1. The number of reported adverse events associated with ethical Kampo formulations related to liver injury

Reported AEs related to liver injury	NEs
Drug-induced liver injury	205
Liver injury	325
Liver cell damage	1
Mixed liver damage	1
Liver function abnormality	467
Liver function test abnormality	1
Liver function test value elevation	3
Liver enzyme elevation	2
Aspartate aminotransferase increase	3
Alanine aminotransferase increase	3
Gamma-glutamyltransferase increase	3
Blood alkaline phosphatase increase	1
Hepatitis	23
Acute hepatitis	57
Fulminant hepatitis	15
Chronic hepatitis	1
Autoimmune hepatitis	5
Cholestatic hepatitis	3
Hepatic failure	3
Acute hepatic failure	3
Jaundice	65
Hepatocellular jaundice	1
Blood bilirubin increase	1
Hyperbilirubinemia	1
Total	1,193

AEs: Adverse events; NEs: Number of reported adverse events.

Table S2. The number of reported adverse events associated with ethical Kampo formulations related to lung injury

Reported AEs related to lung injury	NEs
Interstitial lung disease	852
Lung injury	133
Pneumonia	114
Eosinophilic pneumonia	22
Acute eosinophilic pneumonia	7
Chronic eosinophilic pneumonia	1
Organizing pneumonia	5
Idiopathic organizing pneumonia	1
Cryptogenic organizing pneumonia	1
Pneumonitis	8
Allergic alveolitis	2
Lung fibrosis	2
Idiopathic interstitial pneumonia	1
Acute respiratory distress syndrome	4
Dyspnea	17
Respiratory failure	7
Total	1,177

AEs: Adverse events; NEs: Number of reported adverse events.

Table S3. The number of reported adverse events associated with ethical Kampo formulations related to pseudoaldosteronism

Reported AEs related to PA	NEs	Reported AEs related to PA	NEs
Pseudoaldosteronism	217	Heart failure-related events	46
Pseudoaldosteronism	217	Heart failure	18
Hypertension-related events	13	Congestive heart failure	16
Hypertension	7	Acute heart failure	4
Blood pressure elevation	6	Left ventricular failure	2
Edema-related events	25	Right ventricular failure	1
Edema	7	Lung edema	2
Generalized edema	5	Acute lung edema	2
Peripheral edema	12	Pericardial effusion	1
Body weight increase	1	Arrhythmia-related events	95
Electrolyte abnormality-related events	308	Arrhythmia	7
Hypokalemia	291	Supraventricular arrhythmia	2
Blood potassium decrease	10	Ventricular arrhythmia	4
Hypernatremia	2	Tachyarrhythmia	2
Metabolic alkalosis	5	Extrasystole	3
Muscle injury-related events	176	Supraventricular extrasystole	1
Myopathy	32	Ventricular extrasystole	4
Rhabdomyolysis	104	Ventricular tachycardia	14
Muscle weakness	6	Ventricular fibrillation	14
Paralysis	4	Atrial fibrillation	3
Extremities paralysis	4	Atrioventricular block	1
Extremities paresis	1	Complete atrioventricular block	3
Asthenia	6	Long QT syndrome	6
Blood creatine phosphokinase increase	14	Electrocardiogram long QT	12
Myalgia	1	Torsades de pointes	19
Tetany	1	Other events	9
Myositis	1	Cortisol increase	1
Muscle enzyme elevation	1	Blood cortisol increase	1
Myoglobinuria	1	Renin decrease	1
		Hyperglycemia	4
		Diabetes mellitus	2
		Total	889

AEs: Adverse events; NEs: Number of reported adverse events; PA, pseudoaldosteronism.

Table S4. The number of reported adverse events associated with ethical Kampo formulations related to mesenteric phlebosclerosis

Reported AEs related to MP	NEs
Mesenteric phlebosclerosis	119
Idiopathic mesenteric phlebosclerosis	47
Phlebosclerosis	9
Colitis	14
Ischemic colitis	6
Intestinal obstruction	3
Ileus	6
Digestive tract perforation	5
Colon perforation	3
Peritonitis	5
Colon ulcer	1
Colon stenosis	1
Abdominal pain	3
Lower abdominal pain	1
Total	223

AEs: Adverse events; MP: Mesenteric phlebosclerosis; NRs: Number of reported adverse events.

Table S5. The number of reported adverse events associated with ethical Kampo formulations related to drug eruption

Reported AEs related to drug eruption	NEs
Drug eruption	62
Drug eruption with eosinophilia and systemic symptom	3
Drug-induced dermatitis	5
Eruption	15
Urticaria	4
Eczema	2
Papula	1
Systemic skin eruption	19
Pustular skin eruption	1
Erythema	3
Multiple form erythema	23
Systemic erythema	4
Stevens-Johnson syndrome	20
Mucocutaneous ocular syndrome	2
Toxic epidermal necrolysis	4
Acute generalized exanthematous pustulosis	6
Exfoliative dermatitis	2
Dermatitis	1
Atopic dermatitis	2
Contact dermatitis	1
Psoriasis-like dermatitis	1
Pustular acne	1
Pemphigoid	1
Pustular psoriasis	1
Blister	1
Total	185

AEs: Adverse events; NEs: Number of reported adverse events.

Table S6. List of ethical Kampo formulations in Japanese and Chinese

Ethical Kampo formulations		Ethical Kampo formulations	
In Japanese	In Chinese	In Japanese	In Chinese
Anchusan	An Zhong San	Kyukichoketsuin	Xiong Gui Diao Xue Yin
Bakumondoto	Mai Men Dong Tang	Kyukikyogaito	Xiong Gui Jiao Ai Tang
Bofutsushosan	Fang Feng Tong Sheng San	Makyokansekito	Ma Xing Gan Shi Tang
Boiogito	Fang Yi Huang Qi Tang	Makyoyokukanto	Ma Xing Yi Gan Tang
Bukuryoin	Fu Ling Yin	Maobushisaishinto	Ma Huang Fu Zi Xi Xin Tang
Bukuryoingohangekobokuto	Fu Ling Yin He Ban Xia Hou Pu Tang	Maoto	Ma Huang Tang
Bushirichuto	Fu Zi Li Zhong Tang	Mashiningan	Ma Zi Ren Wan
Byakkokaninjinto	Bai Hu Jia Ren Shen Tang	Mokuboito	Mu Fang Yi Tang
Chikujountanto	Zhu Ru Wen Dan Tang	Nichinto	Er Chen Tang
Chojokito	Diao Wei Cheng Qi Tang	Nijutsuto	Er Zhu Tang
Choreito	Zhu Ling Tang	Ninjin'yoeito	Ren Shen Yang Rong Tang
Choreitogoshimotsuto	Zhu Ling Tang He Si Wu Tang	Ninjinto	Ren Shen Tang
Chotosan	Diao Teng San	Nyoshinsan	Nu Shen San
Choyoto	Chang Yong Tang	Ogikenchuto	Huang Qi Jian Zhong Tang
Daibofuto	Da Fang Feng Tang	Ogonto	Huang Qin Tang
Daijokito	Da Cheng Qi Tang	Orengedokuto	Huang Lian Jie Du Tang
Daikenchuto	Da Jian Zhong Tang	Orento	Huang Lian Tang
Daibotampito	Da Huang Mu Dan Pi Tang	Otsujito	Yi Zi Tang
Daiokanzoto	Da Huang Gan Cao Tang	Rikkosan	Li Xiao San
Daisaikoto	Da Chai Hu Tang	Rikkunshito	Liu Jun Zi Tang
Daisaikotokyoadaio	Da Chai Hu Tang Qu Da Huang	Rokumigan	Liu Wei Wan
Eppikajutsuto	Yue Bi Jia Zhu Tang	Ryokanyomishingeninto	Ling Gan Jiang Wei Xin Xia Ren Tang
Gokoto	Wu Hu Tang	Ryokeijutsukanto	Ling Gui Zhu Gan Tang
Goreisan	Wu Ling San	Ryokyojutsukanto	Ling Jiang Zhu Gan Tang
Gorinsan	Wu Lin San	Ryutanshakanto	Long Dan Xie Gan Tang
Goshajinkigan	Niu Che Shen Qi Wan	Saibokuto	Chai Pu Tang
Goshakusan	Wu Ji San	Saikanto	Chai Xian Tang
Goshuyuto	Wu Zhu Yu Tang	Saikokaryukotsuboreito	Chai Hu Jia Long Gu Mu Li Tang
Hachimijiojan	Ba Wei Di Huang Wan	Saikokeishikankyoto	Chai Hu Gui Zhi Qian Jiang Tang
Hainosankyuto	Pai Nong San Ji Tang	Saikokeishito	Chai Hu Gui Zhi Tang
Hangebyakujutsutemmato	Ban Xia Bai Zhu Tian Ma Tang	Saikoseikanto	Chai Hu Qing Gan Tang
Hangekobokuto	Ban Xia Hou Pu Tang	Saireito	Chai Ling Tang
Hangeshashinto	Ban Xia Xie Xin Tang	Sammotsuogonto	San Wu Huang Qin Tang
Heisan	Ping Wei San	San'oshashinto	San Huang Xie Xin Tang
Hochuekkito	Bu Zhong Yi Qi Tang	Sansoninto	Suan Zao Ren Tang
Inchingoreisan	Yin Chen Wu Ling San	Seihaito	Qing Fei Tang
Inchinkoto	Yin Chen Hao Tang	Seijobofuto	Qing Shang Fang Feng Tang
Ireito	Wei Ling Tang	Seishinrenshin	Qing Xin Lian Zi Yin
Jidabokuippo	Zhi Da Pu Yi Fang	Seishoekkito	Qing Shu Yi Qi Tang
Jiinkokato	Zi Yin Jiang Huo Tang	Senkyuchachosan	Chuan Xiong Cha Diao San
Jiinshihoto	Zi Yin Zhi Bao Tang	Shakanzoto	Zhi Gan Cao Tang
Jinsoin	Can Su Yin	Shakuyakukanzobushito	Shao Yao Gan Cao Fu Zi Tang
Jizusoippo	Zhi Tou Chuang Yi Fang	Shakuyakukanzoto	Shao Yao Gan Cao Tang
Jumihaidokuto	Shi Wei Bai Du Tang	Shichimotsukokato	Qi Wu Jiang Xia Tang
Junchoto	Run Chang Tang	Shigyakusan	Si Ni San
Juzentaihoto	Shi Quan Da Bu Tang	Shikunshito	Si Jun Zi Tang
Kakkonkajutsubuto	Ge Gen Jia Zhu Fu Tang	Shimbuto	Zhen Wu Tang
Kakkonto	Ge Gen Tang	Shimotsuto	Si Wu Tang
Kakkontokasenkyushin'ï	Ge Gen Tang Jia Chuan Xiong Xin Yi	Shimpito	Shen Mi Tang
Kamikihito	Jia Wei Gui Pi Tang	Shin'iseihaito	Xin Yi Qing Fei Tang
Kamishoyosan	Jia Wei Xiao Yao San	Shireito	Si Ling Tang
Kanbakutaisoto	Gan Mai Da Zao Tang	Shishihakuhihito	Zhi Zi Bai Pi Tang
Kanzoto	Gan Cao Tang	Shiunko	Zi Yun Gao
Keigairengyoto	Jing Jie Lian Qiao Tang	Shofusan	Xiao Feng San
Keihito	Qi Pi Tang	Shohangekabukuryoto	Xiao Ban Xia Jia Fu Ling Tang
Keimakukahanto	Gui Ma Ge Ban Tang	Shokenchuto	Xiao Jian Zhong Tang
Keishakuchimoto	Gui Shao Zhi Mu Tang	Shomakakkonto	Sheng Ma Ge Gen Tang
Keishibukuryogankayokuinin	Gui Zhi Fu Ling Wan Jia Yi Yi Ren	Shosaikoto	Xiao Chai Hu Tang
Keishibukuryogan	Gui Zhi Fu Ling Wan	Shosaikotokakikyosekko	Xiao Chai Hu Tang Jia Jie Geng Shi Gao
Keishikajutsubuto	Gui Zhi Jia Zhu Fu Tang	Shoseiryuto	Xiao Qing Long Tang
Keishikakakkonto	Gui Zhi Jia Ge Gen Tang	Sokeikakketsuto	Shu Jing Huo Xue Tang
Keishikakobokuyoninto	Gui Zhi Jia Hou Pu Xing Ren Tang	Tokakujokito	Tao He Cheng Qi Tang
Keishikaogito	Gui Zhi Jia Huang Qi Tang	Tokiinshi	Dang Gui Yin Zi
Keishikaryoujutsubuto	Gui Zhi Jia Ling Zhu Fu Tang	Tokikenchuto	Dang Gui Jian Zhong Tang
Keishikaryukotsuboreito	Gui Zhi Jia Long Gu Mu Li Tang	Tokishakuyakusan	Dang Gui Shao Yao San
Keishikashakuyakudaioto	Gui Zhi Jia Shao Yao Da Huang Tang	Tokishakuyakusanabushi	Dang Gui Shao Yao San Jia Fu Zi
Keishikashakuyakuto	Gui Zhi Jia Shao Yao Tang	Tokishigyakukagoshuyushokyoito	Dang Gui Si Ni Jia Wu Zhu Yu Sheng Jiang Tang
Keishininjinto	Gui Zhi Ren Shen Tang	Tokito	Dang Gui Tang
Keishito	Gui Zhi Tang	Tsudosan	Tong Dao San
Kihito	Gui Pi Tang	Unkeito	Wen Jing Tang
Kikyosekko	Jie Geng Shi Gao	Unseiin	Wen Qing Yin
Kikyoto	Jie Geng Tang	Yokuininto	Yi Yi Ren Tang
Kososan	Xiang Su San	Yokukansan	Yi Gan San
Kumibinroto	Jiu Wei Bing Lang Tang	Yokukansanchimpihange	Yi Gan San Jia Chen Pi Ban Xia

Table S7. Ethical Kampo formulations suspected of being related to liver injury

RO	Ethical Kampo formulations	SR	NEs	RO	Ethical Kampo formulations	SR	NEs
1	Bofutsushosan	+	177	42	Ryutanshakanto	+	6
2	Saireito	+	113	42	Goshajinkigan		6
3	Saikokaryukotsuboreito	+	72	44	Hachimijiogan		5
4	Daikenchuto		45	44	Eppikajutsuto		5
5	Orengedokuto	+	44	44	Ryokeijutsukanto		5
6	Hangeshashinto	+	42	44	Tsudosan		5
7	Otsujito	+	38	48	Goshuyuto		4
7	Saikokeishikankyoto	+	38	48	Daisaikotokyodaio	+	4
9	Saibokuto	+	36	50	Keishikaryukotsuboreito		3
10	Kakkonto		33	50	Yokukansankachimpihange		3
11	Shin'iseihaito	+	32	50	Keishibukuryogankayokuinin		3
12	Yokukansan		26	50	Inchinkoto		3
13	Daisaikoto	+	23	50	Kamikihito		3
13	Keigairengyoto	+	23	55	Byakkokaninjinto		2
13	Seishinrenshiin	+	23	55	Tokishigyakukagoshuyushokyoto		2
16	Rikkunshito		22	55	Sokeikakketsuto		2
17	Saikokeishito	+	21	55	Keishikashakuyakuto		2
18	Shosaikoto	+	19	55	Bukuryoingohangekobokuto		2
18	Bakumondoto		19	60	Kakkontokasenkyushin'i		1
18	Shakuyakukanzoto		19	60	Jumihaidokuto		1
21	Goreisan		18	60	Ninjinto		1
22	Kamishoyosan		17	60	Hangebyakujutsutemmato		1
22	Seijobofuto	+	17	60	Makyokansekito		1
24	Nyoshinsan	+	16	60	Gorinsan	+	1
25	Boiogito		15	60	Jizusoippo		1
25	Tokishakuyakusan		15	60	Goshakusan		1
27	Hochuekkito		14	60	Kososan		1
27	Unseiin	+	14	60	Shimotsuto		1
29	Maoto		13	60	Saikanto	+	1
30	Keishibukuryogan		12	60	Shikunshito		1
31	Seihaito	+	10	60	Daiokanzoto		1
31	Maobushisaishinto		10	60	Tokiinshi		1
33	Hangekobokuto		9	60	Jidabokuippo		1
34	Shoseiryuto		8	60	Chikujountanto		1
34	Nijutsuto	+	8	60	Daibofuto		1
34	Shosaikotokakikyosekko	+	8	60	Shokenchuto		1
34	Sammotsuogonto	+	8	60	Hainosankyuto		1
38	Choreito		7	60	Senkyuchachosan		1
38	Juzentaihoto		7	60	Keishikashakuyakudaioto		1
38	Junchoto	+	7	60	Keishakuchimoto		1
38	Tokakujokito		7	60	Keishikaryoujutsubuto		1

NEs: Number of reported adverse events; RO: Rank order; SR: Scutellariae Radix.

Table S8. Ethical Kampo formulations suspected of being related to lung injury

RO	Ethical Kampo formulations	SR	NEs	RO	Ethical Kampo formulations	SR	NEs
1	Saireito	+	142	42	Maobushisaishinto		4
2	Bofutsushosan	+	108	46	Shimbuto		3
3	Otsujito	+	65	46	Choreito		3
4	Hangeshashinto	+	62	46	Sokeikakketsuto		3
5	Shosaikoto	+	56	46	Keishikashakuyakuto		3
6	Seishinrenshiin	+	50	46	Yokukansankachimpihange		3
7	Saikokaryukotsuboreito	+	46	46	Chikujountanto		3
8	Shakuyakukanzoto		32	46	Kamikihito		3
9	Orengedokuto	+	31	53	Hachimijiojan		2
10	Saibokuto	+	29	53	Shofusan		2
10	Goshajinkigan		29	53	Tokishigyakukagoshuyushokyoto		2
12	Yokukansan		28	53	Ryokeijutsukanto		2
13	Shin'iseihaito	+	27	53	Keishito		2
14	Daisaikoto	+	26	53	Chotosan		2
15	Hochuekkito		24	53	Makyokansekito		2
16	Saikokeishito	+	23	53	Nyoshinsan	+	2
16	Bakumondoto		23	53	Tokiinshi		2
16	Nijutsuto	+	23	53	Jidabokuippo		2
19	Saikokeishikankyoto	+	22	53	Gokoto		2
20	Daikenchuto		20	64	Kamishoyosan		1
21	Shoseiryuto		19	64	Keishikaryukotsuboreito		1
22	Rikkunshito		17	64	Eppikajutsuto		1
22	Junchoto	+	17	64	Goshuyuto		1
22	Unseiin	+	17	64	Byakkokaninjinto		1
25	Keishibukuryogan		15	64	Hangebyakujutsutemmato		1
25	Seihaito	+	15	64	Seijobofuto	+	1
27	Ryutanshakanto	+	14	64	Kihito		1
28	Sammotsuogonto	+	12	64	Shimotsuto		1
29	Boiogito		11	64	Chojokito		1
30	Kakkonto		9	64	Saikoseikanto	+	1
30	Tokishakuyakusan		9	64	Daiokanzoto		1
32	Goreisan		8	64	Shimpito		1
32	Keigairengyoto	+	8	64	Jiinshihoto		1
32	Gorinsan	+	8	64	Shokenchuto		1
32	Mashiningan		8	64	Ryokankyomishingeninto		1
36	Hangekobokuto		7	64	Keishikashakuyakudaioto		1
36	Maoto		7	64	Inchinkoto		1
36	Juzentaihoto		7	64	Seishoekkito		1
36	Shosaikotokakikyosekko	+	7	64	Kikyoto		1
40	Tokakujokito		6	64	Kikyosekko		1
40	San'oshashinto	+	6	64	Kanzoto		1
42	Jumihaidokuto		4	64	Shakuyakukanzobushito		1
42	Keishikajutsubuto		4	64	Kakkonkajutsubuto		1
42	Ninjin'yoeito		4	64	Keishikaogito		1

NEs: Number of reported adverse events; RO: Rank order; SR: Scutellariae Radix.

Table S9. Ethical Kampo formulations suspected of being related to pseudohyperaldosteronism

RO	Ethical Kampo formulations	NEs	RO	Ethical Kampo formulations	NEs
1	Shakuyakukanzoto	397	25	Gokoto	3
2	Yokukansan	171	25	Kikyoto	3
3	Hochuekkito	43	25	Keishikaryoujutsubuto	3
4	Kakkonto	36	25	Shakuyakukanzobushito	3
5	Rikkunshito	24	31	Kakkontokasenkyushin'i	2
6	Bakumondoto	18	31	Otsujito	2
7	Daiokanzoto	15	31	Keishikaryukotsuboreito	2
8	Kamishoyosan	14	31	Maoto	2
9	Juzentaihoto	12	31	Shigyakusan	2
9	Saireito	12	31	Keishikashakuyakuto	2
11	Boiogito	11	31	Kososan	2
11	Bofutsushosan	11	31	Saibokuto	2
13	Ryokeijutsukanto	10	31	Seishinrenshin	2
13	Yokukansankachimpihange	10	40	Saikokeishikankyoto	1
15	Shoseiryuto	9	40	Keishito	1
16	Ninjinto	8	40	Makyokansekito	1
17	Hangeshashinto	7	40	Tokakujokito	1
18	Chotosan	6	40	Kanbakutaisoto	1
19	Saikokeishito	5	40	Tokiinshi	1
19	Byakkokaninjinto	5	40	Tsudosan	1
19	Sokeikakketsuto	5	40	Ninjin'yoeito	1
22	Shosaikoto	4	40	Ryokyojutsukanto	1
22	Keishikajutsubuto	4	40	Keishikashakuyakudaioto	1
22	Kanzoto	4	40	Kumibinroto	1
25	Nichinto	3	40	Kakkonkajutsubuto	1
25	Jidabokuippo	3			

NEs: Number of reported adverse events; RO: Rank order.

Table S10. The ethical Kampo formulations suspected of being related to mesenteric phlebosclerosis

RO	Ethical Kampo formulations	GF	NEs	RO	Ethical Kampo formulations	GF	NEs
1	Orengedokuto	+	57	15	Unseiin	+	2
2	Kamishoyosan	+	54	15	Shimotsuto		2
3	Inchinkoto	+	29	15	Seihaito	+	2
4	Shin'iseihaito	+	13	21	Otsujito		1
5	Shishihakuhito	+	8	21	Saikokaryukotsuboreito		1
6	Kamikihito	+	7	21	Hangeshashinto		1
7	Bofutsushosan	+	5	21	Shofusan		1
7	Daikenchuto		5	21	Tokishakuyakusan		1
9	Keishibukuryogan		4	21	Daiobotanpito		1
9	Hochuekkito		4	21	Byakkokaninjinto		1
11	Anchusan		3	21	Gorinsan	+	1
11	Shosaikoto		3	21	Tokakujokito		1
11	Juzentaihoto		3	21	Chikujountanto		1
11	Seijobofuto	+	3	21	Ogikenchuto		1
15	Hangekobokuto		2	21	Inchingoreisan		1
15	Goreisan		2	21	Mashiningan		1
15	Shoseiryuto		2				

GF: Gardeniae Fructus; NEs: Number of reported adverse events; RO: Rank order.

Table S11. Ethical Kampo formulations suspected of being related to drug eruption

RO	Ethical Kampo formulations	EH	SR	NEs	RO	Ethical Kampo formulations	EH	SR	NEs
1	Kakkonto	+		26	24	Hangeshashinto		+	2
2	Shoseiryuto	+		14	24	Boiogito			2
3	Maoto	+		11	24	Juzentaihoto			2
4	Maobushisaishinto	+		9	24	Tokiinshi			2
5	Bakumondoto			8	24	Ninjin'yoeito			2
5	Daikenchuto			8	32	Anchusan			1
7	Goshajinkigan			7	32	Hangekobokuto			1
8	Rikkunshito			6	32	Keishikajutsubuto			1
9	Hachimijogan			5	32	Keishibukuryogan			1
9	Saikokeishito		+	5	32	Eppikajutsuto	+		1
9	Shakuyakukanzoto			5	32	Shimbuto			1
9	Shosaikotokakikyosekko		+	5	32	Goshuyuto			1
9	Saireito		+	5	32	Ninjinto			1
14	Shosaikoto		+	4	32	Hangebyakujutsutemmato			1
14	Orengedokuto		+	4	32	Chotosan			1
14	Goreisan			4	32	Keigairengyoto		+	1
14	Kamishoyosan			4	32	Keishikashakuyakuto			1
14	Unseiin		+	4	32	Tokakujokito			1
19	Shofusan			3	32	Jizusoippo			1
19	Tokishakuyakusan			3	32	Daibofuto			1
19	Ryokeijutsukanto			3	32	Seishinrenshiin		+	1
19	Hochuekkito			3	32	Bukuryoingohangekobokuto			1
19	Yokukansan			3	32	Inchingoreisan			1
24	Kakkontokasenyushin'i	+		2	32	Senkyuchachosan			1
24	Otsujito		+	2	32	Kyukichoketsuin			1
24	Jumihaidokuto			2					

EH: Ephedrae Herba; NEs: Number of reported adverse events; RO: Rank order; SR: Scutellariae Radix.

Table S12. Ethical Kampo formulations suspected of being related to anaphylaxis

RO	Ethical Kampo formulations	EH	SR	NEs
1	Kakkonto	+		3
2	Shoseiryuto	+		2
2	Kamishoyosan			2
2	Shakuyakukanzoto			2
2	Shosaikotokakikyosekko		+	2
6	Otsujito		+	1
6	Saikokeishikankyoto		+	1
6	Hangekobokuto			1
6	Boiogito			1
6	Maoto	+		1
6	Bakumondoto			1
6	Hangebyakujutsutemmato			1
6	Choreito			1
6	Rikkunshito			1
6	Goshakusan	+		1
6	Jidabokuippo			1
6	Shin'iseihaito		+	1
6	Saireito		+	1
6	Bukuryoingohangekobokuto			1
6	Maobushisaishinto	+		1
6	Kikyoto			1

EH: Ephedrae Herba; NEs: Number of reported adverse events; RO: Rank order; SR: Scutellariae Radix.

Table S13. Ethical Kampo formulations suspected of being related to allergic cystitis

RO	Ethical Kampo formulations	SR	NEs
1	Shosaikoto	+	4
2	Saibokuto	+	2
3	Saikokeishito	+	1
3	Seijobofuto	+	1
3	Bofutsushosan	+	1
3	Ryutanshakanto	+	1
3	Saikoseikanto	+	1
3	Shokenchuto		1
3	Shin'iseihaito	+	1

EH: Ephedrae Herba; NEs: Number of reported adverse events; RO: Rank order; SR: Scutellariae Radix.